Back to top
more

Better Therapeutics (BTTX)

(Delayed Data from OTC)

$0.01 USD

0.01
239,629

0.00 (15.00%)

Updated May 30, 2024 03:13 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status

by Zacks Equity Research

Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

by Zacks Equity Research

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL on the grounds of insufficient data. The stock falls 5%.

Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study

by Zacks Equity Research

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous urticaria. The stock of the company rises 16%.

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

by Zacks Equity Research

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin

by Zacks Equity Research

Orchard (ORTX) is set to be acquired by Kyowa Kirin for a consideration of $17 per American Depositary Share, which amounts to a total transaction value of approximately $478 million. Shares rise 97%.

Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data

by Zacks Equity Research

Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.

Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate

by Zacks Equity Research

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

by Zacks Equity Research

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why

by Zacks Equity Research

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

by Zacks Equity Research

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

by Zacks Equity Research

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.

Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway

by Zacks Equity Research

Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.

Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study

by Zacks Equity Research

Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.

Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients

by Zacks Equity Research

Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.

Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up

by Zacks Equity Research

Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.

Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence, in the EU.

Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod

by Zacks Equity Research

Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

by Zacks Equity Research

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

by Zacks Equity Research

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.

Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up

by Zacks Equity Research

Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.

Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study

by Zacks Equity Research

Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

by Zacks Equity Research

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

by Zacks Equity Research

Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.

Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio

by Zacks Equity Research

Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters.